<DOC>
	<DOC>NCT01723982</DOC>
	<brief_summary>This trial investigates the effects of FE 200440 compared to placebo on implantation rate in women undergoing IVF/ICSI treatment</brief_summary>
	<brief_title>Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine Contractions</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<criteria>Women aged 1837 years Women who have undergone 24 previous fresh in vitro fertilization (IVF) or intracytoplasmatic sperm injection (ICSI) cycles that all resulted in a negative Î²hCG test, despite transfer of at least one embryo/blastocyst of good quality Women who have in the current controlled ovarian stimulation cycle for IVF/ICSI followed the long Gonadotrophin Releasing Hormone (GnRH) agonist or GnRH antagonist protocol, received hCG for triggering of final follicular maturation and have undergone oocyte retrieval for IVF/ICSI with the purpose of fresh transfer Retrieval of at least 6 oocytes in the current controlled ovarian stimulation cycle Subjects should have at least one embryo of good quality available for transfer on day 3, or at least one good quality blastocyst available for transfer on day 5 A total of 6 or more controlled ovarian stimulation cycles for IVF/ICSI Abnormal karyotype Uterine pathology or hydrosalpinx Diagnosed with acquired or congenital thrombophilia disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>37 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>